Cumberland reports ifetroban well-tolerated with positive trend in DMD trial; no stat-sig

CUMBERLAND PHARMACEUTICALS INC

Interim analysis from 25 patients after 6 months; both ifetroban doses well-tolerated.
Positive trend in leg muscle strength but no statistically significant differences at this early point.
Phase II trial evaluating ifetroban for DMD cardiomyopathy; FDA awarded $1M orphan grant.
Company plans to complete studies, analyze data, then decide development path for ifetroban registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.